AR057867A1 - Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos - Google Patents

Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos

Info

Publication number
AR057867A1
AR057867A1 ARP060104226A ARP060104226A AR057867A1 AR 057867 A1 AR057867 A1 AR 057867A1 AR P060104226 A ARP060104226 A AR P060104226A AR P060104226 A ARP060104226 A AR P060104226A AR 057867 A1 AR057867 A1 AR 057867A1
Authority
AR
Argentina
Prior art keywords
pde
treatment
polypeptide
test compound
bladder
Prior art date
Application number
ARP060104226A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR057867A1 publication Critical patent/AR057867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)

Abstract

Composiciones farmacologicas que comprenden inhibidores de PDE-5 y PDE-4, solos o en combinacion, para el tratamiento de trastornos urologicos que comprenden hiperplasia prostática benigna (HPB), síntomas del tracto urinario inferior (STUI) y en particular síntomas irritativos provocados por obstruccion de la salida de la vejiga (OSV) inducida por HPB. Procedimientos de deteccion selectiva para tales inhibidores de PDE-5 y PDE-4 para uso, solos y en combinacion, en la preparacion de medicamentos para el tratamiento de dichos trastornos urologicos. Reivindicacion 1: Un procedimiento de deteccion selectiva para inhibidores de PDE-5 utiles como agentes terapéuticos en el tratamiento de una enfermedad comprendida en un grupo de enfermedades constituido por hiperplasia prostática benigna (HPB), obstruccion de la salida de la vejiga (OSV) y síntomas del tracto urinario inferior (STUI), que comprende las etapas de i) poner en contacto un compuesto de ensayo con un polipéptido de PDE-5, ii) determinar la actividad del polipéptido de PDE-5 a una cierta concentracion del compuesto de ensayo o en ausencia de dicho compuesto de ensayo, iii) determinar la actividad de dicho polipéptido de PDE-5 a una concentracion diferente de dicho compuesto de ensayo, iv) seleccionar al menos un compuesto con efecto inhibitorio sobre el polipéptido de PDE-5. Reivindicacion 15: Una composicion farmacéutica que contiene al menos un compuesto seleccionado del grupo vardenafilo, sildenafilo, tadalafilo, udenafilo, dasantafilo, avanafilo, SLx2101 y LAS34179 o una sal, un hidrato o un hidrato de una sal de los mismos, para el tratamiento de vejiga neurogénica, vejiga hiperactiva y cistitis intersticial.
ARP060104226A 2005-09-29 2006-09-27 Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos AR057867A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05021261 2005-09-29
EP06007776 2006-04-13

Publications (1)

Publication Number Publication Date
AR057867A1 true AR057867A1 (es) 2007-12-26

Family

ID=37831473

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104226A AR057867A1 (es) 2005-09-29 2006-09-27 Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos

Country Status (23)

Country Link
US (1) US20090186896A1 (es)
EP (1) EP1931797A2 (es)
JP (1) JP2009509984A (es)
KR (1) KR20080056250A (es)
AR (1) AR057867A1 (es)
AU (1) AU2006299232A1 (es)
BR (1) BRPI0616633A2 (es)
CA (1) CA2623657A1 (es)
CR (1) CR9840A (es)
DO (1) DOP2006000207A (es)
EC (1) ECSP088311A (es)
GT (1) GT200600442A (es)
IL (1) IL190201A0 (es)
MA (1) MA29880B1 (es)
NO (1) NO20081973L (es)
PE (1) PE20070587A1 (es)
RU (1) RU2435588C2 (es)
SG (1) SG166106A1 (es)
SV (1) SV2009002851A (es)
TN (1) TNSN08147A1 (es)
TW (1) TW200804603A (es)
UY (1) UY29816A1 (es)
WO (1) WO2007039075A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
EP2144605A1 (en) * 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
JP2010540621A (ja) * 2007-10-02 2010-12-24 ドン ア ファーマシューティカル カンパニー リミテッド 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法
EP2222639A1 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
TWI617553B (zh) 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA2933250A1 (en) * 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR20240122604A (ko) 2014-08-12 2024-08-12 주식회사 메지온 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을 개선시키는 방법
WO2016033776A1 (en) 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
PL3562485T3 (pl) * 2018-03-23 2020-11-16 Laboratoires Major Niehormonalne kompozycje i sposoby antykoncepcji u mężczyzn z wykorzystaniem (r)-silodozyny
EP3914701A4 (en) * 2019-01-23 2022-10-19 Path Therapeutics Inc. METHODS OF TREATMENT OF EPILEPSY VIA PHOSPHODIESTERASE 4-(PDE4) INHIBITION

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (es) * 1963-01-16
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
JPH05506011A (ja) * 1990-04-11 1993-09-02 ジ・アップジョン・カンパニー 流動床コーティングによるイブプロフェンの味覚マスキング
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CU23063A3 (es) * 1997-11-12 2005-07-19 Bayer Ag Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
EP1214039A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
JP2003519150A (ja) * 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
WO2002036126A1 (en) * 2000-10-30 2002-05-10 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2002230217B2 (en) * 2001-02-15 2005-02-17 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
IL158738A0 (en) * 2001-05-09 2004-05-12 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2544322C (en) * 2003-11-20 2012-05-08 Astellas Pharma Inc. Agent for treating chronic pelvic pain syndrome
AU2005237607B2 (en) * 2004-04-27 2010-12-16 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
EP1898879A1 (en) * 2005-06-23 2008-03-19 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
EP2144605A1 (en) * 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS

Also Published As

Publication number Publication date
MA29880B1 (fr) 2008-10-03
US20090186896A1 (en) 2009-07-23
CR9840A (es) 2008-10-31
JP2009509984A (ja) 2009-03-12
WO2007039075A3 (en) 2007-06-21
NO20081973L (no) 2008-06-20
IL190201A0 (en) 2008-11-03
BRPI0616633A2 (pt) 2011-06-28
DOP2006000207A (es) 2007-07-15
TNSN08147A1 (en) 2009-07-14
GT200600442A (es) 2007-05-15
SV2009002851A (es) 2009-01-14
SG166106A1 (en) 2010-11-29
WO2007039075A2 (en) 2007-04-12
PE20070587A1 (es) 2007-08-17
ECSP088311A (es) 2008-06-30
TW200804603A (en) 2008-01-16
EP1931797A2 (en) 2008-06-18
RU2008116547A (ru) 2009-11-10
AU2006299232A1 (en) 2007-04-12
RU2435588C2 (ru) 2011-12-10
KR20080056250A (ko) 2008-06-20
UY29816A1 (es) 2007-04-30
CA2623657A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
AR057867A1 (es) Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
Frantz Playing dirty
Grinshtein et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells
US10267787B2 (en) Profiling peptides and methods for sensitivity profiling
RU2009145935A (ru) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений
ES2285230T3 (es) Combinacion sinergica de un ligando alfa-2-delta y un inhibidor de pdev para uso en el tratamiento de dolor.
NO20071512L (no) Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor.
WO2006014665A3 (en) Arylpyrrolidine derivatives as nk-1/ssri antagonists
ATE493401T1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
Xu et al. Structure-activity and structure-property relationships of novel Nrf2 activators with a 1, 2, 4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury
US20180169095A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
US20230183238A1 (en) Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
ES2836905T3 (es) Uso de moduladores negativos de los receptores gaba que contienen subunidades alfa5 como antidepresivos de acción rápida
Alsaikhan et al. Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
US10350204B2 (en) Methods for treating cognitive deficits associated with fragile X syndrome
Chen Mechanisms underlying the lethal and toxic effects of synthetic cathinone analogues
TH87313A (th) สารยับยั้ง pde และสารรวมของมันสำหรับการรักษาความผิดปกติในทางเดินปัสสาวะ
Hassanipour et al. The Expression and Function of Nitric Oxide Synthase Enzyme in Atorvastatin Effects on Morphine-Induced Dependence in Mice
TH87313B (th) สารยับยั้ง pde และสารรวมของมันสำหรับการรักษาความผิดปกติในทางเดินปัสสาวะ
Emil Tsai Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission)
JP2022522068A (ja) 平滑筋の非アドレナリン作動性収縮及び前立腺細胞増殖を阻害するためのオンバンサーティブ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal